82.46
price down icon1.13%   -0.94
after-market 시간 외 거래: 82.46
loading
전일 마감가:
$83.40
열려 있는:
$83.53
하루 거래량:
300.10K
Relative Volume:
0.56
시가총액:
$5.47B
수익:
-
순이익/손실:
$-224.29M
주가수익비율:
-21.14
EPS:
-3.9
순현금흐름:
$-185.06M
1주 성능:
-2.52%
1개월 성능:
+9.95%
6개월 성능:
+5.34%
1년 성능:
+4.43%
1일 변동 폭
Value
$81.05
$84.22
1주일 범위
Value
$80.97
$86.83
52주 변동 폭
Value
$55.53
$113.51

Nuvalent Inc Stock (NUVL) Company Profile

Name
명칭
Nuvalent Inc
Name
전화
508-446-2272
Name
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Name
직원
162
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
NUVL's Discussions on Twitter

NUVL을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NUVL
Nuvalent Inc
82.46 6.07B 0 -224.29M -185.06M -3.90
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Nuvalent Inc Stock (NUVL) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-14 업그레이드 UBS Neutral → Buy
2024-12-30 개시 H.C. Wainwright Buy
2024-10-24 개시 UBS Neutral
2024-08-29 개시 Barclays Overweight
2024-04-17 개시 Jefferies Buy
2024-04-01 업그레이드 Leerink Partners Market Perform → Outperform
2024-02-28 재개 Guggenheim Buy
2024-02-23 개시 Robert W. Baird Outperform
2023-09-27 개시 Stifel Buy
2023-08-08 개시 SVB Securities Market Perform
2023-07-24 개시 Guggenheim Buy
2023-01-18 개시 Wedbush Outperform
2022-06-24 개시 BMO Capital Markets Outperform
모두보기

Nuvalent Inc 주식(NUVL)의 최신 뉴스

pulisher
12:40 PM

Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times

12:40 PM
pulisher
07:19 AM

Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer - Investing.com

07:19 AM
pulisher
07:02 AM

Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial - TipRanks

07:02 AM
pulisher
06:48 AM

Nuvalent doses first patient in phase 3 lung cancer drug trial - Investing.com Australia

06:48 AM
pulisher
06:32 AM

Nuvalent announces initiation of Alkazar phase 3 randomized - MarketScreener

06:32 AM
pulisher
06:30 AM

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - PR Newswire

06:30 AM
pulisher
Jul 20, 2025

Is Nuvalent Inc. a good long term investmentExceptional portfolio growth - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Nuvalent Inc. stockUnbelievable profit margins - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Nuvalent Inc. stock priceOutstanding capital returns - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

Nuvalent Inc. Stock Analysis and ForecastBreakthrough financial growth - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

How high can Nuvalent Inc. stock price go in 2025Profitable Yet Secure Picks - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Nuvalent Inc. stock price move sharplyFree Access to Stock Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Recent Analysts’ Ratings Updates for Nuvalent (NUVL) - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

Nuvalent's Insider Sales and Clinical Milestones: A Balancing Act for Investors - AInvest

Jul 11, 2025
pulisher
Jul 09, 2025

Nuvalent(NUVL) Shares Soar 3.47% on Positive Lung Cancer Data - AInvest

Jul 09, 2025
pulisher
Jul 07, 2025

Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead By Investing.com - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead - Investing.com

Jul 07, 2025
pulisher
Jul 06, 2025

10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey

Jul 06, 2025
pulisher
Jul 05, 2025

Nuvalent (NUVL) Gets a Buy from Goldman Sachs - The Globe and Mail

Jul 05, 2025
pulisher
Jul 03, 2025

Nuvalent (NASDAQ:NUVL) Upgraded at The Goldman Sachs Group - Defense World

Jul 03, 2025
pulisher
Jul 01, 2025

Goldman Sachs initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com India

Jul 01, 2025
pulisher
Jun 30, 2025

Goldman Sachs initiates coverage on Nuvalent stock with Buy rating - Investing.com

Jun 30, 2025
pulisher
Jun 27, 2025

Nuvalent chief development officer Noci sells $314k in shares - Investing.com

Jun 27, 2025
pulisher
Jun 26, 2025

Barclays Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail

Jun 26, 2025
pulisher
Jun 25, 2025

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader - insights.citeline.com

Jun 25, 2025
pulisher
Jun 25, 2025

Nuvalent (NUVL) Receives Raised Price Target from Baird | NUVL Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Nuvalent stock price target raised to $114 from $100 at UBS - Investing.com

Jun 25, 2025
pulisher
Jun 24, 2025

Data keeps Nuvalent on track for rolling zidesamtinib NDA - The Pharma Letter

Jun 24, 2025
pulisher
Jun 24, 2025

Transcript : Nuvalent, Inc.Special Call - MarketScreener

Jun 24, 2025
pulisher
Jun 24, 2025

Nuvalent Reports Positive Pivotal Data From ARROS-1 Study Of Zidesamtinib - Nasdaq

Jun 24, 2025
pulisher
Jun 23, 2025

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib - Finansavisen

Jun 23, 2025
pulisher
Jun 19, 2025

Nuvalent Appoints Christy Oliger to Board of Directors - The Malaysian Reserve

Jun 19, 2025
pulisher
Jun 18, 2025

Nuvalent appoints former Genentech oncology executive to board - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Nuvalent appoints Christy Oliger to board of directors - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Nuvalent Adds Former Genentech Oncology SVP to Board Ahead of 2026 Launch Plans | NUVL Stock News - Stock Titan

Jun 18, 2025

Nuvalent Inc (NUVL) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):